BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Schizophrenia clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for schizophrenia: 84 (51 sponsors; 18 newly posted in the last 180 days, 6 stopped in the last 180 days; 12 new-entrant sponsors). Momentum score 20.2, rank 29 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 1, Phase 1 17, Phase 2 18, Phase 3 30, Phase 4 3, N/A 15.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Neurocrine Biosciences NBIX | 6 | P2 1, P3 4, P4 1 | 0 | 0 |
| Bristol-Myers Squibb BMY | 8 | P3 3, NA 3, P1 1, P4 1 | 1 | 0 |
| Karuna Therapeutics, Inc., a Bristol Myers Squibb company | 3 | P3 3 | 1 | 1 |
| Alkermes, Inc. ALKS | 2 | P3 2 | 0 | 0 |
| Bostal Drug Delivery Co., Ltd new entrant | 2 | P3 2 | 2 | 0 |
| Jiangsu Hansoh Pharmaceutical Co., Ltd. new entrant | 2 | P3 2 | 2 | 0 |
| LB Pharmaceuticals Inc. LBRX | 2 | P3 2 | 0 | 0 |
| Otsuka Pharmaceutical Co., Ltd. | 2 | P3 2 | 0 | 0 |
| Intra-Cellular Therapies, Inc. | 2 | P3 1, P2 1 | 0 | 0 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | P1 1, P3 1 | 0 | 1 |
| Vanda Pharmaceuticals VNDA | 2 | P3 1, P4 1 | 0 | 0 |
| Chengdu Kanghong Pharmaceutical Group Co., Ltd. | 1 | P3 1 | 0 | 0 |
| Gedeon Richter Plc. | 1 | P3 1 | 0 | 1 |
| Minerva Neurosciences NERV | 1 | P3 1 | 0 | 0 |
| Newron Pharmaceuticals SPA | 1 | P3 1 | 0 | 1 |
| Qilu Pharmaceutical Co., Ltd. | 1 | P3 1 | 0 | 0 |
| Reviva Pharmaceuticals RVPH | 1 | P3 1 | 0 | 0 |
| SyneuRx International (Taiwan) Corp | 1 | P3 1 | 0 | 0 |
| Luye Pharma Group Ltd. | 5 | P1 4, P2 1 | 0 | 0 |
| MapLight Therapeutics MPLT | 3 | P2 3 | 0 | 0 |
| Vigonvita Life Sciences | 3 | P1 2, P2 1 | 1 | 0 |
| CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 2 | NA 2 | 0 | 1 |
| Eli Lilly and Company LLY | 2 | NA 1, P2 1 | 0 | 0 |
| Novartis Pharmaceuticals NVS | 2 | P1 1, P2 1 | 1 | 0 |
| AbbVie ABBV | 1 | P2 1 | 0 | 0 |
New-entrant sponsors: Bostal Drug Delivery Co., Ltd, Jiangsu Hansoh Pharmaceutical Co., Ltd..
Recently stopped trials
- NCT03513549 Nova Pneuma Inc. - suspended: Low commercial usage of ADASUVE resulting in low patient enrollment. NPI has placed this study on hold until market uptake increases and mak Observational Study Evaluating the Safety of ADASUVEĀ® in Agitation Associated With Schizophrenia or Bipolar I Disorder
- NCT00508157 Otsuka Pharmaceutical Development & Commercialization, Inc. - terminated: Slow Accrual A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Antipsychotics in the Treatment of Schizophr
- NCT03896945 Otsuka Pharmaceutical Development & Commercialization, Inc. - terminated: Based on the Interim Analysis outcome and recommendation by the DMC, Otsuka approved termination of the study based on futility. Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia
- NCT01129674 Denovo Biopharma LLC - terminated: The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population. A Long-Term, Open-Label, Study on Schizophrenia
- NCT01487083 Denovo Biopharma LLC - terminated: The decision to stop the trial was based on efficacy results in the overall schizophrenia participant population. A Long-Term Safety Study of Pomaglumetad Methionil in Schizophrenia
- NCT05443724 AbbVie - terminated: The study was terminated due to business reasons, not safety reasons. A Study to Evaluate Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12-15 est. | P3 | Gedeon Richter Plc. | NCT03817502 Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia | Schizophrenia | recruiting | 330 |
| 2026-12-31 est. | P1/P2 | Mapi Pharma Ltd. | NCT07185815 Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatmen | Schizophrenia; Bipolar I Disorder; Major Depressive Disorder | recruiting | 24 |
FDA decision events (last 12 months and upcoming)
| Date | Event | Status | Company | Drug | Source |
|---|---|---|---|---|---|
| 2026-12-12 | PDUFA date (company-disclosed) | pending | Vanda Pharmaceuticals Inc. VNDA | imsidolimab | PDUFA December 12, 2026 - Vanda Pharmaceuticals Inc. (imsidolimab) |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11 est. | P2 | NeuShen Therapeutics | NCT07521683 A Phase II Clinical Study to Evaluate the Efficacy and Safety of NS-136 in the Treatment of Schizophrenia | Schizophrenia(Acute) | enrolling by invitation | 150 |
| 2026-10-23 est. | P3 | Qilu Pharmaceutical Co., Ltd. | NCT06799559 Study on the Efficacy and Safety of QLM1016 in Schizophrenia | Schizophrenia | active not recruiting | 402 |
| 2026-10-20 est. | P3 | Otsuka Pharmaceutical Development & Commercialization, Inc. | NCT06894212 A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia | Schizophrenia | active not recruiting | 538 |
| 2026-09-30 est. | P2/P3 | SyneuRx International (Taiwan) Corp | NCT03094429 An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBenĀ®, as an A | Refractory Schizophrenia | recruiting | 287 |
| 2026-09-09 | P2 | Kynexis B.V. | NCT07191483 A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia | Cognitive Impairment Associated With Schizophrenia (CIAS) | completed | 149 |
| 2026-09 est. | P3 | Alkermes, Inc. ALKS | NCT05303064 Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder | Schizophrenia; Bipolar I Disorder | recruiting | 220 |
| 2026-06-04 | P2 | MapLight Therapeutics MPLT | NCT07038876 A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia | Schizophrenia | completed | 307 |
| 2026-06 est. | P3 | Chengdu Kanghong Pharmaceutical Group Co., Ltd. | NCT06589817 A Double-Blind, Randomized Comparative Study of Carliprazine and Aripiprazole in Patients with Acute Schizophrenia | Acute Schizophrenia | not yet recruiting | 376 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "schizophrenia"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.